Biotechnology
Filter News
Found 46,688 articles
-
Eascra Biotech Research Blasts Off with Ax-2 Launch
5/19/2023
Research from Eascra Biotech will be onboard Axiom Mission 2, a private crew mission to the International Space Station set to launch Sunday May 21 from Kennedy Space Station.
-
Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa
5/19/2023
Krystal Biotech, Inc. (the Company) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, today announced the US Food and Drug Administration (FDA) has approved VYJUVEK™ (beremagene geperpavec-svdt) for the treatment of patients six months of age or older with dystrophic epidermolysis bullosa (DEB).
-
Celularity Announces Phase 1 Data Showing That MLASC Therapy in Patients With Crohn’s Disease May Be a Therapeutic Option to Manage Inflammatory Bowel Diseases and Prevent Fistula Formation
5/19/2023
Celularity Inc. (Nasdaq: CELU) (“Celularity”) announced results from an exploratory analysis of Phase 1 data evaluating alterations in gene and protein signatures associated with reduced inflammation and fistula formation resulting from therapy with mesenchymal‐like adherent stromal cells (MLASCs) in adult patients with Crohn’s disease (CD).
-
AMYRIS COMPLETES LICENSE FOR SUPPLY OF SUSTAINABLE SQUALENE
5/19/2023
Amyris, Inc. today announced that it has signed an exclusive license agreement with British specialty chemicals company Croda International Plc, or the supply of sustainable squalene.
-
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
5/19/2023
Exicure, Inc., announced it received a notice of non-compliance from Nasdaq Stock Market LLC on May 17, 2023 notifying the Company that, as a result of the Company’s failure to timely file its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, the Company is not in compliance with Nasdaq Listing Rule 5250, which requires listed companies to timely file all periodic financial reports with the U.S. Securities and Exchange Commission.
-
Daxor Corporation Announces Proposed Underwritten Public Offering - May 19, 2023
5/19/2023
DAXOR CORPORATION, the global leader in blood volume measurement technology, announces that it has commenced an underwritten public offering of shares of its common stock.
-
KaliVir Immunotherapeutics Announces New In Vivo Data Demonstrating Superior Therapeutic Efficacy of VET3-TGI at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
5/19/2023
KaliVir Immunotherapeutics, Inc. announced the presentation of new data on its lead pre-clinical candidate VET3-TGI at the American Society of Gene & Cell Therapy 26th Annual Meeting.
-
Tessera Therapeutics Presents New Data Demonstrating the Potential of Gene Writing™ Technology at the American Society of Gene and Cell Therapy 26th Annual Meeting
5/19/2023
Tessera Therapeutics presented progress across multiple platforms and preclinical programs including increased efficiency in correcting the SCD mutation in preclinical models, increased efficiency in correcting the most common mutation in PKU in mouse and NHP models, and a first-time demonstration of efficient in vivo rewriting in AATD.
-
Chroma Medicine Announces Data Demonstrating the Benefits of Epigenetic Editing for Multiplex Gene Regulation at ASGCT 2023
5/19/2023
Chroma Medicine, Inc., a genomic medicine company pioneering single-dose epigenetic editing therapeutics, presented data demonstrating the advantages of epigenetic editing for multiplex gene regulation at the American Society of Gene & Cell Therapy 26th Annual Meeting in Los Angeles.
-
NervGen Pharma Announces Results of Annual General Meeting of Shareholders
5/19/2023
NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announces the results of its Annual General Meeting of Shareholders ("AGM") held on May 17, 2023.
-
Epic Bio Presents Preclinical Data on EPI-321 for Facioscapulohumeral Muscular Dystrophy at ASGCT 26th Annual Meeting
5/19/2023
Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, presented promising preclinical data supporting development of EPI-321 for the treatment of facioscapulohumeral muscular dystrophy.
-
American Aires Inc. Announces Filing of Q1/2023 Financial Statements and MD and A
5/19/2023
American Aires Inc. (CSE: WIFI) (OTC Pink: AAIRF) ("Aires" or the "Company"), a leader in scientifically-proven EMF modulation technology, is pleased to announce the filing of its unaudited Financial Statements and the MD&A for the first quarter of 2023, covering the period January 1 to March 31, 2023
-
Telo Genomics Announces Private Placement of Units
5/19/2023
Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to announce a non-brokered private placement of units ("Units") at a price of $0.25 per Unit for gross proceeds of $2,000,000 (the "Offering").
-
Enveric Biosciences to Participate in 2023 BIO International Convention in Boston
5/19/2023
Enveric Biosciences, Inc. today announced its participation in this year’s 2023 BIO International Convention, which is being held in Boston, MA, June 5-8, 2023.
-
Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023
5/19/2023
Alterity Therapeutics today announced that David Stamler, M.D., Chief Executive Officer of Alterity will present at the SHARE Series Monday Management Update on Monday, May 22, 2023, at 11:00 am ET or 1:00am AEST Tuesday, May 23, 2023.
-
According to the FDA, the majority of therapies prescribed for children were not tested in pediatric populations. The new guidance aims to change that.
-
Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer
5/18/2023
Zymeworks Inc. today announced the departure of Neil Klompas, President and Chief Operating Officer.
-
Legend Biotech Reports First Quarter 2023 Results and Recent Highlights
5/18/2023
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today reported its first quarter 2023 unaudited financial results.
-
PDS Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of VERSATILE-002 Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer
5/18/2023
PDS Biotechnology Corporation announced the completion of enrollment in the immune checkpoint inhibitor naïve group of its VERSATILE-002 Phase 2 trial for the treatment of recurrent or metastatic human papillomavirus 16-positive head and neck cancer.
-
Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer
5/18/2023
Replay, a genome writing company reprogramming biology by writing and delivering big DNA, announced the appointment of Arun Balakumaran, M.D., Ph.D., as Chief Medical Officer, effective 22 May.